Single stranded DNA binding antibodies in patients with obstructive jaundice

Area of Science:

• Immunology
• Gastroenterology
• Oncology

Background:

• Biliary tract stones and tumors, as well as pancreatic tumors, are significant health concerns.
• Autoantibodies, such as single-stranded DNA (ssDNA) binding antibodies, are implicated in various autoimmune and neoplastic conditions.

Purpose of the Study:

• To investigate the presence and significance of ssDNA binding antibodies in patients with biliary tract diseases and pancreatic tumors.
• To explore correlations between ssDNA binding antibodies and clinical parameters like jaundice, its duration, and serum markers.

Main Methods:

• Assessed the incidence of ssDNA binding antibodies in patient cohorts with biliary tract stones, biliary tract tumors, and pancreatic tumors.
• Analyzed the association between antibody levels and the presence/type of jaundice (obstructive vs. non-obstructive), duration of obstructive jaundice, serum total bilirubin, and serum IgM.

Main Results:

• Elevated ssDNA binding antibodies were detected in patients with biliary tract stones and/or tumors of the biliary tract or pancreas.
• The incidence of ssDNA binding antibodies was higher in obstructive jaundice (50%) compared to non-obstructive jaundice (22%), increasing with duration.
• A significant positive correlation was found between ssDNA binding antibody levels and serum IgM, but not with serum total bilirubin.

Conclusions:

• ssDNA binding antibodies may serve as a potential biomarker in patients with biliary tract diseases and pancreatic tumors.
• The presence and levels of these antibodies are associated with obstructive jaundice and IgM levels, suggesting a role in the pathogenesis or as a marker of disease severity.